nach oben

Archives of Dermatological Research

Erschienen in:

01.05.2024 | REVIEW

Topical steroids or emollients: does order matter?

verfasst von: Kripa Ahuja, Peter A. Lio

Erschienen in: Archives of Dermatological Research | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Topical corticosteroids, topical steroid-sparing agents, and emollients are all used to treat atopic dermatitis. However, there are no formal guidelines dictating the order and timing in which these topical modalities should be applied. Additionally, the order of application may change drug absorption, efficacy, and distribution. This is especially important for patients with atopic dermatitis. These patients have a dysfunctional skin barrier, which can lead to greater systemic absorption of drugs. Moreover, children already have an increased rate of systemic absorption due to a higher ratio of body surface area to body weight. Thus, the order of application of topical regimens is of the utmost importance in pediatric dermatology. This manuscript presents an updated review of the literature with a focus on guiding clinicians toward the best practices from the available resources.

Ng SY, Begum S, Chong SY (2016) Does order of application of emollient and topical corticosteroids make a difference in the severity of atopic eczema in children? Pediatr Dermatol 33(2):160–164. https://doi.org/10.1111/pde.12758CrossRefPubMed

Surber C, Robertis J, Reinau D (2022) Topical corticosteroid or emollient product: which to apply first? J Eur Acad Dermatol Venereol. https://doi.org/10.1111/jdv.18797CrossRefPubMed

Rai R, Barathi M, Srinivas C (2011) The efficacy of clobetasol propionate with varying dilutions of emollient determined by histamine wheal suppression test. Indian J Dermatol 56(5):527. https://doi.org/10.4103/0019-5154.87146CrossRefPubMedPubMedCentral

Huang A, Cho C, Leung DYM, Brar K (2017) Atopic dermatitis: early treatment in children. Curr Treat Options Allergy 4(3):355–369. https://doi.org/10.1007/s40521-017-0140-6CrossRefPubMedPubMedCentral

Avena-Woods C (2017) Overview of atopic dermatitis. Am J Manag Care 23(8 Suppl):S115–S123PubMed

Madsen S, Price KN, Shi VY, Lio PA (2020) Pearls in mitigating application pain of topical nonsteroidal agents. Dermatology 236(5):477–480. https://doi.org/10.1159/000508771CrossRefPubMed

Danby SG, Draelos ZD, Gold LFS et al (2022) Vehicles for atopic dermatitis therapies: more than just a placebo. J Dermatol Treat 33(2):685–698. https://doi.org/10.1080/09546634.2020.1789050CrossRef

Nikolovski J, Stamatas GN, Kollias N, Wiegand BC (2008) Barrier function and water-holding and transport properties of infant stratum corneum are different from adult and continue to develop through the first year of life. J Invest Dermatol 128(7):1728–1736. https://doi.org/10.1038/sj.jid.5701239CrossRefPubMed

Wiedersberg S, Naik A, Leopold CS, Guy RH (2009) Pharmacodynamics and dermatopharmacokinetics of betamethasone 17-valerate: assessment of topical bioavailability. Br J Dermatol 160(3):676–686. https://doi.org/10.1111/j.1365-2133.2008.08757.xCrossRefPubMed

10.

Voegeli D (2017) Topical steroids and emollients in atopic eczema—which should be applied first? Pract Nurs 28(1):14–20. https://doi.org/10.12968/pnur.2017.28.1.14CrossRef

11.

Loden M (2003) Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol 4(11):771–788. https://doi.org/10.2165/00128071-200304110-00005CrossRefPubMed

12.

N’Da D (2014) Prodrug strategies for enhancing the percutaneous absorption of drugs. Molecules 19(12):20780–20807. https://doi.org/10.3390/molecules191220780CrossRefPubMedPubMedCentral

13.

Fujii M (2021) The pathogenic and therapeutic implications of ceramide abnormalities in atopic dermatitis. Cells 10(9):2386. https://doi.org/10.3390/cells10092386CrossRefPubMedPubMedCentral

14.

Halling-Overgaard AS, Kezic S, Jakasa I, Engebretsen KA, Maibach H, Thyssen JP (2017) Skin absorption through atopic dermatitis skin: a systematic review. Br J Dermatol 177(1):84–106. https://doi.org/10.1111/bjd.15065CrossRefPubMed

15.

Danby SG, Andrew PV, Taylor RN et al (2022) Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis. Clin Exp Dermatol 47(6):1154–1164. https://doi.org/10.1111/ced.15141CrossRefPubMedPubMedCentral

16.

Udompataikul M, Srisatwaja W (2011) Comparative trial of moisturizer containing licochalcone A vs. hydrocortisone lotion in the treatment of childhood atopic dermatitis: a pilot study: Treatment of childhood atopic dermatitis. J Eur Acad Dermatol Venereol 25(6):660–665. https://doi.org/10.1111/j.1468-3083.2010.03845.xCrossRefPubMed

17.

Quadri M, Lotti R, Bonzano L et al (2021) A novel multi-action emollient plus cream improves skin barrier function in patients with atopic dermatitis: in vitro and clinical evidence. Skin Pharmacol Physiol 34(1):8–18. https://doi.org/10.1159/000513055CrossRefPubMed

18.

Oranges T, Dini V, Romanelli M (2015) Skin physiology of the neonate and infant: clinical implications. Adv Wound Care 4(10):587–595. https://doi.org/10.1089/wound.2015.0642CrossRef

19.

D’Addezio A, Shelesky G (2022) Reevaluating the measurement of potency of topical corticosteroids. Am Fam Physician 105(6):570PubMed

20.

Hengge UR, Ruzicka T, Schwartz RA, Cork MJ (2006) Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 54(1):1–15. https://doi.org/10.1016/j.jaad.2005.01.010CrossRefPubMed

21.

Tanei R (2020) Atopic dermatitis in older adults: a review of treatment options. Drugs Aging 37(3):149–160. https://doi.org/10.1007/s40266-020-00750-5CrossRefPubMedPubMedCentral

22.

Egeberg A, Schwarz P, Harsløf T et al (2021) Association of potent and very potent topical corticosteroids and the risk of osteoporosis and major osteoporotic fractures. JAMA Dermatol 157(3):275. https://doi.org/10.1001/jamadermatol.2020.4968CrossRefPubMed

23.

Purnamawati S, Indrastuti N, Danarti R, Saefudin T (2017) The role of moisturizers in addressing various kinds of dermatitis: a review. Clin Med Res 15(3–4):75–87. https://doi.org/10.3121/cmr.2017.1363CrossRefPubMedPubMedCentral

24.

Dekio I, Morita E (2011) The weight of a finger-tip unit of ointment in 5-gram tubes. J Dermatol Treat 22(5):302–303. https://doi.org/10.3109/09546631003797098CrossRef

25.

Long CC, Finlay AY (1991) The finger-tip unit—a new practical measure. Clin Exp Dermatol 16(6):444–447. https://doi.org/10.1111/j.1365-2230.1991.tb01232.xCrossRefPubMed

26.

Eichenfield LF, Boguniewicz M, Simpson EL et al (2015) Translating atopic dermatitis management guidelines into practice for primary care providers. Pediatrics 136(3):554–565. https://doi.org/10.1542/peds.2014-3678CrossRefPubMed

27.

Sheary B (2019) Topical steroid withdrawal: a case series of 10 children. Acta Derm Venereol 99(6):551–556. https://doi.org/10.2340/00015555-3144CrossRefPubMed

28.

Voegeli D (2008) The effect of washing and drying practices on skin barrier function. J Wound Ostomy Continence Nurs 35(1):84–90. https://doi.org/10.1097/01.WON.0000308623.68582.d7CrossRefPubMed

29.

Nankervis H, Thomas KS, Delamere FM et al (2017) What is the evidence base for atopic eczema treatments? A summary of published randomized controlled trials. Br J Dermatol 176(4):910–927. https://doi.org/10.1111/bjd.14999CrossRefPubMed

30.

Regeneron Pharmaceuticals. A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of dupilumab administered concomitantly with topical corticosteroids in patients, ≥6 years to <12 years of age, with severe atopic dermatitis. clinicaltrials.gov; 2020. https://clinicaltrials.gov/ct2/show/results/NCT03345914. Accessed 27 Dec 2022

31.

Gooderham MJ, Forman SB, Bissonnette R et al (2019) Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol 155(12):1371–1379. https://doi.org/10.1001/jamadermatol.2019.2855CrossRefPubMedPubMedCentral

32.

Silverberg JI, Simpson EL, Thyssen JP et al (2020) Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 156(8):863–873. https://doi.org/10.1001/jamadermatol.2020.1406CrossRefPubMed

33.

Society PCD. Eczema—atopic eczema. Primary care dermatology society. https://www.pcds.org.uk/clinical-guidance/atopic-eczema. Accessed 26 Dec 2022

34.

Children’s patient information leaflets. https://www.wsh.nhs.uk/Patients-and-visitors/Patient-information-leaflets/Childrens-patient-information-leaflets.aspx?GenericListPL_List_GoToPage=16. Accessed 26 Dec 2022

35.

NHSGGC Guidelines. https://www.clinicalguidelines.scot.nhs.uk/nhsggc-guidelines/nhsggc-guidelines/. Accessed 26 Dec 2022

36.

Patient information leaflets—Oxford University Hospitals. https://www.ouh.nhs.uk/patient-guide/leaflets/. Accessed 26 Dec 2022

37.

Eczema: How to Use Moisturisers and Topical Steroids—HealthXchange. https://www.healthxchange.sg:443/head-neck/skin-health/eczema-moisturisers-topical-steroids. Accessed 26 Dec 2022

38.

Emollients and Steroid Treatments. Allergy UK | National Charity. http://allergyuk.org. Accessed 26 Dec 2022

39.

Liu L, Ong G (2018) A randomized, open-label study to evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream in combination with regular emollient skin care in reducing the risk of relapse in pediatric patients with stabilized atopic dermatitis. J Dermatol Treat 29(5):501–509. https://doi.org/10.1080/09546634.2017.1401211CrossRef

40.

Wohlrab J, Staubach P, Augustin M et al (2018) S2k guidelines for the use of topical preparations on the skin: Guidelines for topical preparations. JDDG J Dtsch Dermatol Ges 16(3):376–392. https://doi.org/10.1111/ddg.13473CrossRefPubMed

41.

Eczema. Seattle Children’s Hospital. https://www.seattlechildrens.org/conditions/a-z/eczema/. Accessed 26 Dec 2022

42.

Atopic Dermatitis | Texas Children’s Hospital. https://www.texaschildrens.org/departments/dermatology/conditions-we-treat/atopic-dermatitis. Accessed 26 Dec 2022

43.

November 22 SH, 2017. Put the Lotion Down! Moisturizing Eczema-Prone Skin. AtopicDermatitis.net. https://atopicdermatitis.net/living/moisturizing-eczema-prone-skin. Accessed 26 Dec 2022

44.

Information. http://www.nottinghameczema.org.uk/information/index.aspx#Guidelines. Accessed 26 Dec 2022

45.

Managing eczema in winter and year round: a parents guide. Published August 8, 2021. https://www.hopkinsmedicine.org/health/wellness-and-prevention/managing-eczema-in-winter-and-year-round-a-parents-guide. Accessed 26 Dec 2022

46.

Eczema Medication and Treatment | Allergy & Asthma Network. https://allergyasthmanetwork.org/what-is-eczema/eczema-treatment-options/. Accessed 26 Dec 2022

47.

York and Scarborough Teaching Hospitals NHS Foundation Trust—Patient information leaflets. https://www.yorkhospitals.nhs.uk/your-visit/patient-information-leaflets/. Accessed 26 Dec 2022

48.

Anne Nguyen. Opzelura (Ruxolitinib) topical: uses, side effects, dosage. Verywell Health. https://www.verywellhealth.com/opzelura-ruxolitinib-topical-6385862. Accessed 28 Dec 2022

49.

Atopic dermatitis treatment: Crisaborole (Eucrisa®) ointment. https://www.aad.org/public/diseases/eczema/types/atopic-dermatitis/crisaborole. Accessed 28 Dec 2022

50.

Clinical Review Report: Crisaborole Ointment, 2% (Eucrisa): (Pfizer Canada Inc.): Indication: for topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older. Canadian agency for drugs and technologies in health. 2019. http://www.ncbi.nlm.nih.gov/books/NBK542348/. Accessed 28 Dec 2022

51.

Pimecrolimus (Topical Route) proper use—mayo clinic. https://www.mayoclinic.org/drugs-supplements/pimecrolimus-topical-route/proper-use/drg-20068138. Accessed 28 Dec 2022

52.

Moisturizer and lotion for eczema: everything you need to know. National eczema association. https://nationaleczema.org/eczema/treatment/moisturizing/. Accessed 27 Dec 2022

53.

Flohr C (2004) Evidence based management of atopic eczema. Arch Dis Child Educ Pract 89(2):ep35–ep39. https://doi.org/10.1136/adc.2004.050237CrossRef

54.

Introduction | Atopic eczema in under 12s: diagnosis and management | Guidance | NICE. https://www.nice.org.uk/guidance/cg57/chapter/Introduction#treatment-2. Accessed 26 Dec 2022

55.

Topical corticosteroids and withdrawal reactions. GOV.UK. https://www.gov.uk/guidance/topical-corticosteroids-and-withdrawal-reactions. Accessed 26 Dec 2022

56.

Zealand (www.bka.co.nz) S designed and developed by bka interactive ltd Auckland, New. Topical steroids | Health Navigator NZ. Health Navigator New Zealand. https://www.healthnavigator.org.nz/medicines/t/topical-steroids/. Accessed 26 Dec 2022

57.

Hydrocortisone (topical) for eczema—medicines for children. https://www.medicinesforchildren.org.uk/medicines/hydrocortisone-topical-for-eczema/. Accessed 26 Dec 2022

58.

Wollenberg A, Christen-Zäch S, Taieb A et al (2020) ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 34(12):2717–2744. https://doi.org/10.1111/jdv.16892CrossRefPubMed

59.

Sathishkumar D, Moss C (2016) Topical therapy in atopic dermatitis in children. Indian J Dermatol 61(6):656. https://doi.org/10.4103/0019-5154.193677CrossRefPubMedPubMedCentral

60.

Eczema: steroids and other topical medications. Institute for quality and efficiency in health care (IQWiG). 2017. https://www.ncbi.nlm.nih.gov/books/NBK424899/. Accessed 26 Dec 2022

61.

blue_admin. FAQs. National Eczema Society. Published February 10, 2020. https://eczema.org/information-and-advice/faqs/. Accessed 26 Dec 2022

Titel: Topical steroids or emollients: does order matter?
verfasst von: Kripa Ahuja
Peter A. Lio
Publikationsdatum: 01.05.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Dermatological Research / Ausgabe 4/2024
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-024-02837-0

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2024

Herpes zoster infection in pregnancy: features and consequences

Understanding patient demographics and treatment strategies observed in the follicular occlusion triad and tetrad

More yeast, more problems?: reevaluating the role of Malassezia in seborrheic dermatitis

Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA–CHE): a new clinician reported outcome measure of CHE severity

Optimizing intralesional triamcinolone acetonide treatment for isolated nail psoriasis: a pilot, intra-subject randomized controlled trial